索拉非尼治疗中国晚期肝细胞癌：病毒和肿瘤状态的预后因

StephenW

Medicine (Baltimore). 2019 Nov;98(44):e17692. doi: 10.1097/MD.0000000000017692.
Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Lee SW1,2, Lee TY1,2, Peng YC1,3, Yang SS1,3, Yeh HZ1,3, Chang CS1,2.
Author information

1
    Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital.
2
    Department of Internal Medicine, Chung Shan Medical University, Taichung.
3
    Department of Internal Medicine, Yang Ming University, Taipei, Taiwan.

Abstract

Sorafenib is of proven efficacy in treating patients of hepatocellular carcinoma (HCC). Our study was aimed to determine the factors influence the sorafenib efficacy.We evaluated data of HCC patients receiving sorafenib from June 2012 to October 2016. All HCC cases were of the Barcelona Clinic Liver Cancer (BCLC) classification stage C. The exclusion criteria: those of BCLC classification stage A or B, with the absence or co-infection of hepatitis B (HBV) and hepatitis C (HCV). The presence of HBV, HCV, macoscopic vascular invasion (MVI) or extrahepatic spread (EHS) was recorded for each patient. Time-to-progression (TTP) and overall survival (OS) were analyzed.Among a total of 90 HCC patients, 48 (53.3%) had HBV infection, 42 (46.7%) had HCV infection, 51 (56.7%) had MVI, and 39 (43.3%) had EHS. Patients with HCV infection showed better TTP and OS than those with HBV infection. Patients with EHS had a longer TTP and OS than those with MVI. For patients with HBV infection, those with EHS had a longer TTP (mean 4.60 vs 2.64 months, P = .002) and OS (mean 6.65 vs 4.53 months, P = .045) compared to those with MVI. Among those with MVI, patients with HBV infection had a poorer TTP (mean 2.64 vs 4.74 months, P = .019) and shorter OS (mean 4.53 vs 7.00 months, P = .059) compared to those with HCV infection.HCC patients with HCV infection or with the presence of EHS showed better sorafenib efficacy.

PMID:
    31689794
DOI:
    10.1097/MD.0000000000017692

StephenW

医学（巴尔的摩）。 2019年11月; 98（44）：e17692。 doi：10.1097 / MD.0000000000017692。
索拉非尼治疗中国晚期肝细胞癌：病毒和肿瘤状态的预后因素研究。
Lee SW1,2，Lee TY1,2，Peng YC1,3，Yang SS1,3，Yeh HZ1,3，Chang CS1,2。
作者信息

1个
    台中荣民总医院内科消化内科。
2
    台中中山医科大学内科。
3
    阳明大学内科，台湾台北。

抽象

索拉非尼在治疗肝细胞癌（HCC）患者中已证明具有疗效。我们的研究旨在确定影响索拉非尼疗效的因素。我们评估了2012年6月至2016年10月接受索拉非尼的HCC患者的数据。所有HCC病例均属于巴塞罗那临床肝癌（BCLC）分类阶段C。排除标准：那些BCLC分级为A或B的阶段，没有或同时感染了乙型肝炎（HBV）和丙型肝炎（HCV）。记录每位患者的HBV，HCV，镜下血管浸润（MVI）或肝外扩散（EHS）。分析了进展时间（TTP）和总生存期（OS）。总共90例HCC患者中，HBV感染48例（53.3％），HCV感染42例（46.7％），MVI 51例（56.7％） ，其中39位（43.3％）拥有EHS。 HCV感染的患者显示出比HBV感染的患者更好的TTP和OS。 EHS患者的TTP和OS比MVI患者的更长。对于HBV感染的患者，与MVI患者相比，EHS患者的TTP较长（平均4.60比2.64个月，P = 0.002）和OS（平均6.65 vs 4.53个月，P = 0.045）。在MVI患者中，与HCV感染者相比，HBV感染患者的TTP较差（平均2.64 vs 4.74个月，P = .019）和OS较短（平均4.53 vs 7.00个月，P = .059）。 HCV感染或存在EHS表现出更好的索拉非尼疗效。

PMID：
    31689794
DOI：
    10.1097 / MD.0000000000017692

StephenW

https://journals.lww.com/md-jour ... tients_with.54.aspx